“Latest Stem Cells News”

Vet-Stem Inc. announced that over 8000 animals have now been treated with Vet-Stem cell therapy.

Vet-Stem began providing stem cells to veterinarians in 2004 and has now provided stem cells for the treatment of over 8,000 animals. Vet-Stem was the first company to introduce rapid turnaround stem cell services in the US.

After providing stem cells for thousands of horses, Vet-Stem pioneered stem cell therapy in dogs and cats and is now the world leader in Regenerative Veterinary Medicine. The rapid adoption of stem cell therapy by equine veterinarians and horse owners provided a springboard for use in small animal veterinary medicine.

Greater than 75% of horses treated with Vet-Stem cell therapy for tendon and ligament injuries are able to return to their previous level of performance. Dog owners report that greater than 80% of dogs treated with Vet-Stem cell therapy have an improved quality of life.

Incoming search terms:

Historic Hurd Hall on Johns Hopkins’ East Baltimore campus was filled to capacity on Jan. 13 with students, faculty and staff waiting to hear five scientists—all in the early part of their careers—describe their novel ideas on how to cure metastatic cancer.

The five were finalists, chosen from among 44 entrants, in a competition on creative thinking named for John Rangos Sr., chairman of the Rangos Family Foundation, who funded the awards. Each scientist had 10 minutes to present his or her idea and answer questions from a panel of faculty judges, who would select the winners based on the novelty and scientific merit of their ideas, as well as the feasibility of future clinical applications of their proposals (…)

First up to the podium was medical oncology fellow and eventual fifth-place winner Kevin Cheung, who proposes turning back the clock on cancer cells by reprogramming them into germ cells. He suggests that the reason testicular and other germ cell tumors have high cure rates is because of their undifferentiated state. Just as scientists have created immature pluripotent stem cells from adult cells, Cheung says that the same could be done with cancer cells. By age reversing resistant cancer cells, he proposes to make them sensitive to conventional chemotherapy (…)

The overall prize went to radiation oncology resident Sharabi for his idea titled “Specific Immune Response Against Testicular Cancer: A Proposed Mechanism for Long-Term Remission.”

Incoming search terms:

Adipose Stem Cell Heart Attack Trial Data Published in Journal of the American College of Cardiology; Cytori’s APOLLO Trial Demonstrated Safety & Feasibility and Improvements in Cardiac Function

Cytori Therapeutics announced today the publication of previously reported six-month outcomes from APOLLO, the Company’s European clinical trial evaluating adipose-derived stem and regenerative cells (ADRCs) in patients with acute myocardial infarction (heart attack or AMI), as Research Correspondence in the Journal of the American College of Cardiology. The APOLLO trial was a 14-patient, prospective, randomized, double-blind, placebo-controlled, feasibility trial (Phase I/IIA) evaluating autologous ADRCs extracted with the Company’s proprietary Celution® System for the treatment of patients suffering from acute myocardial infarction.

In the APOLLO trial all patients were treated with standard-of-care and subsequently underwent an abdominal liposuction. Each patient’s adipose tissue was processed by the Celution® System where ADRCs were extracted, washed and concentrated into a syringe of clinical grade cells. Within 36 hours of the myocardial infarction and no longer than 24 hours after undergoing percutaneous coronary intervention, patients received an injection of either 20 million ADRCs (n=10) or a placebo (n=4).

Incoming search terms:

Advanced Cell Technology, a leader in the field of regenerative medicine, today announced treatment of the first patient in its Phase 1/2 clinical trial for Stargardt’s macular dystrophy (SMD) using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs). The surgery was performed on Friday, Jan. 20, at the Moorfields Eye Hospital in London by a team of surgeons led by Professor James Bainbridge, consultant surgeon at Moorfields and Chair of Retinal Studies at University College London. The patient successfully underwent the procedure without any complications. ACT and Moorfields Eye Hospital received clearance in September from the U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) to begin this trial in Europe.

“Our clinical trial program for hESC-derived RPE cells has taken another critical step as we move forward with treating patients at Moorfields Eye Hospital,” said Gary Rabin, chairman and chief executive officer of ACT. “The treatment of the first patient in Europe is tangible evidence that stem cell research and development of cell therapies is making progress. It is a milestone for scientists, stem cell advocates and patients hoping for cures as well as much as it is one for ACT. Stargardt’s macular dystrophy affects up to 100,000 patients in Europe and North America, and causes progressive vision loss often ending with blindness. We are honored to be working with Professor Bainbridge at Moorfields Eye Hospital, and are very pleased with the smooth progress of the trial thus far.”

Incoming search terms:

Image via Wikipedia

Scientists have improved the sight of two people who were almost blind by injecting their eyes with stem cells from embryos.

The two women, both registered as blind, saw their vision improve in a matter of weeks after being given the embryo-derived cells in the US safety trial.

The breakthrough holds out the hope of a cure in the future for age-related macular degeneration, which currently affects some 500,000 people in Britain.
The results, published this week in The Lancet, provide a major boost for the field of stem cell reseach.

Professor Daniel Brison, of the North West Embryonic Stem Cell Centre in Manchester, said: “This is a very exciting moment for embryonic stem cell therapies.
This is the first peer-reviewed scientific report showing that cells derived from human embryonic stem cells can be transplanted safely into a patient with no sign of complications (…)

Incoming search terms:

Cells grown in culture are not alone: They are constantly communicating with one another by sending signals through their culture media that are picked up and transmitted by other cells in the media. When thousands of cells are cultured together in a dish, there are hundreds of thousands of these signals present every minute, all competing to be heard.

Scientists trying to direct cells to do useful things — like causing stem cells to turn into neurons or heart cells — typically try to overcome these signals by adding their own exogenous factors. These exogenous factors are often added at saturating concentrations, blanketing the cells with a particular growth factor or cytokine to activate specific pathways to produce a desired outcome, such as controlling stem cell differentiation. However, the constant din of cell communications is still present, causing alternate and perhaps opposing pathways to be stimulated.

This unstoppable secretion by cells in culture makes it difficult to determine the exact “recipe” of exogenous factors needed to elicit a specific phenotype, particularly in fast-growing cells like embryonic stem cells. MIT researchers Laralynne Przybyla, a graduate student in biology, and Joel Voldman, associate professor of electrical engineering and computer science, report in a paper published this week in Proceedings of the National Academy of Sciences how they were able to silence this din by using a microfluidic device to culture embryonic stem cells under continuous liquid flow (known as perfusion) such that factors secreted by the cells were removed before they could be transmitted to other cells. They used this device to investigate the influence of these factors on stem cells.

Incoming search terms: